Graphite Bio CFO Alethia Young resigns; CEO Josh Lehrer to assume PFO/PAO roles

LENZ Therapeutics, Inc.

Alethia Young resigns as CFO, effective June 30, 2023, to pursue other opportunities.
Resignation not related to any disagreement with the company or its management.
CEO Josh Lehrer appointed as Principal Financial Officer and Principal Accounting Officer effective July 1, 2023.
Dr. Lehrer has served as CEO since April 2020; prior roles at Global Blood Therapeutics and Genentech.
Ms. Young will remain through June 30 to ensure orderly transition.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alethia Young

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

LENZ · LENZ Therapeutics, Inc.

Effective: 2023-06-30
Successor: Josh Lehrer
Filed: June 23, 2023, 7:59 PM ET

On June 19, 2023, Alethia Young, the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Graphite Bio, Inc. (the “Company”), notified the Company of her decision to resign, effective at the close of business on June 30, 2023.

Role change

Josh Lehrer

Principal Financial Officer and Principal Accounting Officer

LENZ · LENZ Therapeutics, Inc.

Effective: 2023-07-01
Filed: June 23, 2023, 7:59 PM ET

The Company intends to appoint Josh Lehrer, the Company’s Chief Executive Officer, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer effective immediately following Ms. Young’s departure.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alethia Young resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at LENZ Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

On June 19, 2023, Alethia Young, the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Graphite Bio, Inc. (the “Company”), notified the Company of her decision to resign, effective at the close of business on June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Josh Lehrer was appointed as Principal Financial Officer and Principal Accounting Officer at LENZ Therapeutics, Inc..

Action: appointed
Role: Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

The Company intends to appoint Josh Lehrer, the Company’s Chief Executive Officer, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer effective immediately following Ms. Young’s departure.

View on SEC.gov

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029499

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.